|Elimination half-life||12–18 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||343.423 g·mol−1|
|3D model (JSmol)|
6β-Naltrexol, or 6α-hydroxynaltrexone, is a major active metabolite of naltrexone formed by hepatic dihydrodiol dehydrogenase which acts as a potent, peripherally selective opioid neutral antagonist. Relative to naltrexone, 6β-naltrexol has about half the affinity for the μ-opioid receptor, but is present at approximately 10–30-fold higher concentrations at steady state due to extensive first-pass metabolism of the parent drug. 6β-Naltrexol was itself investigated as an opioid antagonist, specifically for the treatment of opioid-induced constipation, and was found to be effective and well tolerated, but was not further pursued.
- Dean R, Bilsky EJ, Negus SS (12 March 2009). Opiate Receptors and Antagonists: From Bench to Clinic. Springer Science & Business Media. pp. 269–. ISBN 978-1-59745-197-0.
- Smith HS (21 February 2013). Opioid Therapy in the 21st Century. Oxford University Press. pp. 69–. ISBN 978-0-19-984497-5.
- Cote CJ, Lerman J, Anderson BJ (2013). A Practice of Anesthesia for Infants and Children: Expert Consult - Online and Print. Elsevier Health Sciences. pp. 148–. ISBN 1-4377-2792-1.
- Davis MP, Glare PA, Hardy J (28 May 2009). Opioids in Cancer Pain. Oxford University Press. pp. 41–. ISBN 978-0-19-923664-0.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|